chronic nonbacterial prostatitis (IIIB)
Conditions
Interventions
Experimental group:Take Life Enhancer probiotic capsules orally, twice a day, one capsule each time
Tamsulosin hydrochloride sustained-release capsules, once per night, one capsule per time.
Control Group:Oral placebo, twice a day, one tablet each time
Sponsors
Shanghai Fourth People's Hospital Affiliated to Tongji University
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1) Age range from 18 to 50 years old; 2) Typical symptoms of chronic prostatitis type IIIB (varying degrees of urinary tract irritation and pelvic discomfort) 3) NIH-CPSI score = 15 points; 4) Medical history exceeding 3 months; 5) B-ultrasound examination: The size of the prostate is normal; 6) Prostate fluid routine white blood cells<10/HP.
Exclusion criteria
Exclusion criteria: 1) Previous history of neurological damage (such as in patients with neurogenic bladder dysfunction); 2) Suspected of prostate cancer, urethral tumor or bladder cancer cancer; 3) Individuals with a history of prostate surgery or invasive treatment (such as balloon angioplasty, transurethral microwave hyperthermia, urethral stent implantation, etc.); 4) Individuals with a history of urethral stricture or malformation; 5) Acute urinary system infections; 6) Patients with lower ureteral stones; 7) Severe heart, liver, and kidney dysfunction; 8) Testicular, epididymal, and spermatic cord diseases; 9) Individuals with allergic constitution or allergic to the ingredients of this product; 10) Those who have taken other drugs that affect this trial within the past month; 11) Individuals who cannot understand or complete the experiment, as well as those without legal capacity or self-awareness; 12) Simultaneously participating in other clinical drug trials; Individuals who participate in similar drug trials within one month but meet the inclusion criteria after a one month washout period are eligible to participate in this clinical study. 13) There are other factors that may affect the results of this experiment, or based on the judgment of the researcher, it is not appropriate to enter the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIH-CPSI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal microbiota; | — |
Countries
China
Contacts
Public ContactYonglian Zhang/ Tie Zhou
Shanghai Fourth People's Hospital Affiliated to Tongji University
Outcome results
None listed